Beam Therapeutics Inc. (BEAM) vs uniQure N.V. (QURE)

Beam Therapeutics Inc. and uniQure N.V. are both Biotechnology companies. Beam Therapeutics Inc. and uniQure N.V. are of similar size ($2.7B and $2.6B). Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against 30.2%. Beam Therapeutics Inc. has the higher net margin (−55.5% vs −1,350.7%) and the lower return on invested capital (−1,599.3% vs 0.00%). Across the 18 metrics below, Beam Therapeutics Inc. leads on 16 and uniQure N.V. on 2.

Valuation

Metric BEAM QURE Biotechnology median
P/E n/m n/m 7.88
P/S 16.23 135.63 11.47
P/B 2.37 7.82 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 9.48 95.34 10.73
Earnings yield (3.38%) (10.49%) (28.84%)
Free cash flow yield (14.72%) (6.46%) (23.03%)

Profitability

Metric BEAM QURE Biotechnology median
Gross margin 100.00% 92.49% 65.16%
Operating margin (242.27%) (1,071.53%) 0.00%
Net margin (55.45%) (1,350.73%) 0.00%
Free cash flow margin (238.90%) (864.67%) 0.00%
Return on equity (8.18%) (157.61%) (57.72%)
Return on assets (6.23%) (32.13%) (49.22%)
Return on invested capital (1,599.30%) 0.00% 0.00%

Growth

Metric BEAM QURE Biotechnology median
Revenue growth (TTM) 158.88% 30.24% 5.64%
EPS growth (last fiscal year) 82.31% 29.67% —
Revenue growth, 5-year CAGR 466.27% (15.57%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM QURE Biotechnology median
Debt to equity 0.09 0.15 0.00
Current ratio 14.57 10.01 4.73
Net debt to EBITDA 3.30 3.36 0.96

Dividend

Metric BEAM QURE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BEAM QURE Biotechnology median
Market cap 2.55b 2.67b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack